SOD1 and amyotrophic lateral sclerosis: These findings are supported by multiple studies using adeno-associated viral vectors to deliver CRISPR/Cas9 components, leading to significant reduction of mutant SOD1 in the central nervous system and amelioration of ALS phenotypes [83,84,85].